Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group has secured approval from China’s National Medical Products Administration for its Calcium Chloride to be registered as a bulk drug for existing market preparations. This regulatory green light broadens the group’s injectable portfolio with a key additive used to treat calcium deficiency, tetany, vitamin D deficiency, allergic disorders and certain toxicities, signaling incremental expansion of its product base and potential strengthening of its position in China’s hospital drug market.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a Hong Kong-listed pharmaceutical group engaged in the research, development and production of drug products and bulk pharmaceuticals. The company focuses on injectable medicines and related formulations for hospital and clinical use in mainland China and other markets, supplying essential therapies for critical and chronic conditions.
Average Trading Volume: 8,087,672
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.41B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.